login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

First patients treated with Chemosat in Germany


Tuesday, 28 Feb 2012 11:12
Chemosaturation
Chemosaturation

Delcath Systems announced on 27 February that the first patients in Germany have been treated with the Delcath Hepatic Chemosat Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the company announced with the hospital in December 2011.


Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.


Thomas J Vogl, director of the Institute for Diagnostic and Interventional Radiology at JW Goethe, said, “We believe this technology has significant potential to help control cancers in the liver. We are pleased to be the first cancer centre to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer.”


“Delcath’s partnership with JW Goethe reinforces the potential of Chemosat,” said Eamonn P Hobbs, president and CEO, Delcath. “We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another Chemosat treatment centre and treating patients in the continent’s largest market is another step forward in the commercialisation of this technology.”




Add New Comment

Related Items


Most popular


Aneurysm screening should be revisited, BMJ article defends
Friday, 06 Mar 2015
Aneurysm screening for men over 65 should be revisited as it is unknown whether the benefits outweigh the harms, argue researchers in The BMJ. Aneurysm screening should be revisited, BMJ article defends

Monday, 02 Mar 2015
Cardinal Health has announced plans to acquire Johnson & Johnson’s Cordis business, a global manufacturer of cardiology and endovascular devices, for US$1.944 billion in cash. Cardinal Health announces offer to acquire Cordis

Live from SIR 2015: Image-guided treatment shown to break the migraine cycle
Sunday, 01 Mar 2015
88% of patients report using less pain-relief medicine after intranasal sphenopalatine ganglion blocks. Live from SIR 2015: Image-guided treatment shown to break the migraine cycle

Features


The challenges of measuring response in interventional oncology
Monday, 30 Mar 2015
An overview of three treatments: ablation, chemoembolization and selective interval radiation therapy, should clarify the challenges of determining tumour response in interventional oncology, write M... The challenges of measuring response in interventional oncology

Revolutionary focused ultrasound still needs to address limitations
Monday, 30 Mar 2015
Alessandro Napoli writes that therapeutic ultrasound still has some technological hurdles that need to be overcome, despite his success with the treatment over the past five years. Revolutionary focused ultrasound still needs to address limitations

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions